Cue Biopharma Stock Discussion

$Cue Biopharma(CUE.US)$
Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting
Cue Biopharma has presented updated data from its Phase 1 trial of CUE-101 at the 2024 ASCO Annual Meeting, revealing promising results for HPV+ head and neck cancer. The combination of CUE-101 and pembrolizumab in first-line (1L) treatment showed a 46% overall response rate (ORR) and a 96% 12-month overall survival (OS). ...

$Cue Biopharma(CUE.US)$ In at 7.74

$CUE— STOCK & OPTION PLAY
NEED IT TO BREAK OVER: $15.40
key indicator for MORE uptrend $15.55
confirmation uptrend - $16.16
mini breakout - $16.37
full breakout - $17.31
SEMI PARABOLIC - $18.25
stop loss - $14.31
support - $12.98. $Cue Biopharma(CUE.US)$